Management of Antiplatelet Therapy in GI Bleeding After Drug-Eluting Stent Placement

Critical Safety Principle

Withholding both antiplatelet agents simultaneously dramatically accelerates stent thrombosis, with a median time to thrombosis of only 7 days when both drugs are stopped, compared to 122 days when only clopidogrel is withheld 1
Continuation of aspirin alone significantly delays the onset of coronary events in patients on dual antiplatelet therapy (DAPT), making this the safest approach during acute GI bleeding 2, 3

Continue aspirin indefinitely without interruption throughout the bleeding episode and endoscopic management 1, 2, 3
Temporarily withhold the P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) during the acute bleeding phase 1, 2, 3

Ticagrelor should be resumed within 2-3 days after successful endoscopic hemostasis, as it is a reversible P2Y12 inhibitor with platelet function returning within 3-5 days after discontinuation 2, 3
Clopidogrel can be delayed up to 5 days after endoscopic hemostasis, as it irreversibly inhibits platelet function with recovery taking approximately 5 days 2, 3
Prasugrel can be delayed up to 5-7 days after endoscopic hemostasis, as it also irreversibly inhibits platelets with the longest recovery time of approximately 7 days 2, 3

Consult with the patient's cardiologist before resuming the P2Y12 inhibitor to assess individual thrombotic risk based on stent type, timing since implantation, and clinical presentation 1

For acute coronary syndrome (ACS) patients with DES, the standard recommendation is at least 12 months of DAPT, making any interruption particularly risky 5, 6, 7
For non-ACS indications with DES, 12 months of DAPT is recommended if bleeding risk is not prohibitive 5, 6, 7

PPIs should be used in all patients with a history of prior GI bleeding who require DAPT, making this a Class I recommendation 5, 6, 7
High-dose PPI therapy should be administered as continuous infusion for 72 hours after successful endoscopic hemostasis 4

In Asian patients, there is additional rationale for withholding clopidogrel while continuing aspirin due to the high prevalence (up to 25%) of CYP2C19 slow metabolizers who may have reduced clopidogrel efficacy when combined with high-dose PPIs 2, 3

Never discontinue both aspirin and P2Y12 inhibitor simultaneously—this is the single strongest risk factor for catastrophic stent thrombosis 1
Do not delay endoscopy to normalize coagulation parameters—proceed with endoscopic hemostasis while maintaining aspirin therapy 1
Avoid NSAIDs during and after the bleeding episode, as they further increase bleeding risk in patients requiring ongoing antiplatelet therapy 4
Do not restart P2Y12 inhibitors too early—allow adequate time for endoscopic hemostasis and initial mucosal healing based on the specific agent's pharmacology 2, 3